ArticleThe oncologist2025

Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate.

Katayoun Moini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.